JP7065589B2 - ＩＬ－１β血清濃度低下用発酵乳、ＣＸＣＬ１血清濃度低下用発酵乳、癌に伴うＩＬ－１βの過度な血清濃度上昇の抑制用発酵乳、または、癌に伴うＣＸＣＬ１の過度な血清濃度上昇の抑制用発酵乳 - Google Patents

ＩＬ－１β血清濃度低下用発酵乳、ＣＸＣＬ１血清濃度低下用発酵乳、癌に伴うＩＬ－１βの過度な血清濃度上昇の抑制用発酵乳、または、癌に伴うＣＸＣＬ１の過度な血清濃度上昇の抑制用発酵乳 Download PDF

Info

Publication number
JP7065589B2
JP7065589B2 JP2017210401A JP2017210401A JP7065589B2 JP 7065589 B2 JP7065589 B2 JP 7065589B2 JP 2017210401 A JP2017210401 A JP 2017210401A JP 2017210401 A JP2017210401 A JP 2017210401A JP 7065589 B2 JP7065589 B2 JP 7065589B2
Authority
JP
Japan
Prior art keywords
serum concentration
fermented milk
suppressing
cxcl1
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017210401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019081733A5 (enExample
JP2019081733A (ja
Inventor
啓誠 川鍋
真梨枝 中村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Co Ltd
Original Assignee
Meiji Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Co Ltd filed Critical Meiji Co Ltd
Priority to JP2017210401A priority Critical patent/JP7065589B2/ja
Priority to US16/650,184 priority patent/US11638431B2/en
Priority to CN201880064288.5A priority patent/CN111201026B/zh
Priority to PCT/JP2018/040016 priority patent/WO2019087993A1/ja
Publication of JP2019081733A publication Critical patent/JP2019081733A/ja
Publication of JP2019081733A5 publication Critical patent/JP2019081733A5/ja
Application granted granted Critical
Publication of JP7065589B2 publication Critical patent/JP7065589B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2017210401A 2017-10-31 2017-10-31 ＩＬ－１β血清濃度低下用発酵乳、ＣＸＣＬ１血清濃度低下用発酵乳、癌に伴うＩＬ－１βの過度な血清濃度上昇の抑制用発酵乳、または、癌に伴うＣＸＣＬ１の過度な血清濃度上昇の抑制用発酵乳 Active JP7065589B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2017210401A JP7065589B2 (ja) 2017-10-31 2017-10-31 ＩＬ－１β血清濃度低下用発酵乳、ＣＸＣＬ１血清濃度低下用発酵乳、癌に伴うＩＬ－１βの過度な血清濃度上昇の抑制用発酵乳、または、癌に伴うＣＸＣＬ１の過度な血清濃度上昇の抑制用発酵乳
US16/650,184 US11638431B2 (en) 2017-10-31 2018-10-29 Fermented milk and polysaccharide with cancerous cachexia inhibitory effect
CN201880064288.5A CN111201026B (zh) 2017-10-31 2018-10-29 具有癌性恶病质抑制作用的发酵乳和多糖类
PCT/JP2018/040016 WO2019087993A1 (ja) 2017-10-31 2018-10-29 癌性悪液質抑制作用を有する発酵乳および多糖類

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017210401A JP7065589B2 (ja) 2017-10-31 2017-10-31 ＩＬ－１β血清濃度低下用発酵乳、ＣＸＣＬ１血清濃度低下用発酵乳、癌に伴うＩＬ－１βの過度な血清濃度上昇の抑制用発酵乳、または、癌に伴うＣＸＣＬ１の過度な血清濃度上昇の抑制用発酵乳

Publications (3)

Publication Number Publication Date
JP2019081733A JP2019081733A (ja) 2019-05-30
JP2019081733A5 JP2019081733A5 (enExample) 2020-11-26
JP7065589B2 true JP7065589B2 (ja) 2022-05-12

Family

ID=66331935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017210401A Active JP7065589B2 (ja) 2017-10-31 2017-10-31 ＩＬ－１β血清濃度低下用発酵乳、ＣＸＣＬ１血清濃度低下用発酵乳、癌に伴うＩＬ－１βの過度な血清濃度上昇の抑制用発酵乳、または、癌に伴うＣＸＣＬ１の過度な血清濃度上昇の抑制用発酵乳

Country Status (4)

Country Link
US (1) US11638431B2 (enExample)
JP (1) JP7065589B2 (enExample)
CN (1) CN111201026B (enExample)
WO (1) WO2019087993A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7065589B2 (ja) 2017-10-31 2022-05-12 株式会社明治 ＩＬ－１β血清濃度低下用発酵乳、ＣＸＣＬ１血清濃度低下用発酵乳、癌に伴うＩＬ－１βの過度な血清濃度上昇の抑制用発酵乳、または、癌に伴うＣＸＣＬ１の過度な血清濃度上昇の抑制用発酵乳
CN113861303B (zh) * 2021-10-21 2023-04-21 华南理工大学 一种从德氏乳杆菌和嗜热链球菌发酵酸奶中分离出的胞外多糖及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014027925A (ja) 2012-06-25 2014-02-13 Meiji Co Ltd 菌体外多糖産生乳酸菌用培地、菌体外多糖産生菌の製造方法、菌体外多糖、菌体外多糖の製造方法、及びヨーグルトの製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2211578C (en) * 1995-02-13 2010-09-21 Chugai Seiyaku Kabushiki Kaisha Muscle protein proteolysis inhibiting agent containing il-6 receptor antibody
JP2009537582A (ja) 2006-05-24 2009-10-29 ディーエスエム アイピー アセッツ ビー．ブイ． 有機化合物の新しい用途
WO2007140613A1 (en) 2006-06-06 2007-12-13 Mcgill University Fermented milk product and use thereof
US7901925B2 (en) * 2006-06-23 2011-03-08 Bojrab Gregory G Lactobacillus delbrueckii ssp. bulgaricus strain and compositions
EP2203551B1 (en) 2007-10-20 2013-08-21 Université de Liège Bifidobacterial species
AU2009240643B2 (en) 2008-04-23 2014-03-06 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
CA2761573A1 (en) 2009-05-11 2010-11-18 Nestec S.A. Bifidobacterium longum ncc2705 (cncm i-2618) and immune disorders
CA2818467A1 (en) 2009-11-18 2011-05-26 Murray Goulburn Co-Operative Co. Limited Recombinant microorganisms
US9585920B2 (en) * 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
JP6016326B2 (ja) * 2009-12-09 2016-10-26 株式会社明治 乳酸菌のスクリーニング方法
BG66937B1 (bg) * 2012-03-07 2019-08-15 "Дафлорн" Оод Асоциация от пробиотични млечнокисели микроорганизми за получаване на диетични млечни продукти
CA2921820C (en) * 2013-08-26 2021-10-12 Meiji Co., Ltd. Antibody titer-increasing agent using lactic acid bacterium
CN104905246A (zh) * 2015-04-24 2015-09-16 劲膳美生物科技股份有限公司 恶性肿瘤特定全营养配方食品
JP6952609B2 (ja) * 2016-02-03 2021-10-20 株式会社明治 発酵乳の製造方法及び発酵乳
JP7017864B2 (ja) * 2017-04-21 2022-02-09 株式会社明治 サイトカイン産生制御剤
JP7065589B2 (ja) 2017-10-31 2022-05-12 株式会社明治 ＩＬ－１β血清濃度低下用発酵乳、ＣＸＣＬ１血清濃度低下用発酵乳、癌に伴うＩＬ－１βの過度な血清濃度上昇の抑制用発酵乳、または、癌に伴うＣＸＣＬ１の過度な血清濃度上昇の抑制用発酵乳

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014027925A (ja) 2012-06-25 2014-02-13 Meiji Co Ltd 菌体外多糖産生乳酸菌用培地、菌体外多糖産生菌の製造方法、菌体外多糖、菌体外多糖の製造方法、及びヨーグルトの製造方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AGE，2013年，Vol. 35，pp. 1311-1326
Cytotechnology，2002, Vol.40, No.1-3，pp.67-73
Drugs [オンライン］，2006年，Vol. 66，pp. 1371-1387，[令和4年1月29日検索] 、インターネット＜URL：https://link.springer.com/article/10.2165/00003495-200666100-00006＞
International Journal of Cancer，2004, Vol.111, No.4，pp.592-595
PLOS ONE，2014, Vol.9, No.7, e102436，pp.1-10
心身医，2016年，Vol. 56, No. 10，pp. 1013-1022
日本化学療法学会雑誌，1996年，Vol. 44, No. 12，pp. 879-882
日本化学療法学会雑誌，1998年，Vol. 46, No. 2，pp. 87-89
日本調理科学会誌，2013, Vol.46, No.2，pp.129-133

Also Published As

Publication number Publication date
CN111201026A (zh) 2020-05-26
US11638431B2 (en) 2023-05-02
US20200296979A1 (en) 2020-09-24
WO2019087993A1 (ja) 2019-05-09
CN111201026B (zh) 2023-09-19
JP2019081733A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
US10925906B2 (en) Composition for improving brain function for neonates
JP2024111238A (ja) インターロイキン－２３産生促進用組成物およびＲｅｇ３ファミリータンパク質の発現誘導用組成物
JP2023175938A (ja) 糖代謝改善用組成物
CN108367034A (zh) 面向婴儿的感染防御剂
HK1254529A1 (zh) 面向婴儿的抗过敏剂
JP6916042B2 (ja) 抗原特異的インターフェロンγ産生促進用組成物
WO2012073924A1 (ja) 子宮内膜症の予防及び／又は改善剤及びこれを含んでなる飲食品組成物
JP2019513390A (ja) 食物、エネルギーおよび／または脂肪の摂取を減少させるためのビフィズス菌（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ）
JPWO2019182160A1 (ja) 母乳成分増強用組成物
JP6773368B2 (ja) 免疫発達促進剤
JP7065589B2 (ja) ＩＬ－１β血清濃度低下用発酵乳、ＣＸＣＬ１血清濃度低下用発酵乳、癌に伴うＩＬ－１βの過度な血清濃度上昇の抑制用発酵乳、または、癌に伴うＣＸＣＬ１の過度な血清濃度上昇の抑制用発酵乳
CN106659222A (zh) 肌醇和益生菌及其用途
JPWO2021025154A1 (ja) 学童期の記憶能向上のための乳幼児用組成物
JPWO2020116511A1 (ja) ノロウイルス感染抑制用組成物
JP2019081733A5 (enExample)
WO2015087919A1 (ja) 抗菌ペプチド誘導剤
JP2021107400A (ja) 肥満抑制剤
JP2013119546A (ja) 不安及び／又は多動性の改善剤
JP7181954B2 (ja) 高いＡｈＲ活性化能を有する乳酸菌
WO2018199130A1 (ja) 知的作業能力向上用組成物および認知能力向上用組成物
JP7266384B2 (ja) チーズのｎ－ヘキサン抽出物を有効成分とする血管平滑筋細胞遊走抑制用組成物
WO2025005236A1 (ja) Ｆｕｓｏｂａｃｔｅｒｉｕｍ属菌の制御用組成物及びその利用
JP5851242B2 (ja) チオレドキシン誘導活性を有する乳酸菌ならびにチオレドキシンを介する生体傷害の予防および／または改善用の飲食品および医薬品
CN120225074A (zh) 肌肉肌醇和预防加速生长

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220426

R150 Certificate of patent or registration of utility model

Ref document number: 7065589

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R150 Certificate of patent or registration of utility model

Ref document number: 7065589

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150